Internal Medicine, Medical Oncology · Cleveland, OH
NPI
1922170430
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2500 Metrohealth Dr
Cleveland, OH, 44109
Phone (216) 778-7800
Groups this clinician bills Medicare through
Medicare paid, 2024
$1,546
47 services
Medicare patients, 2024
31
Average age 73
Drug cost, 2024
$4.2M
534 prescriptions
Company payments, 2025
$6,904
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Tse was code 99441 (telephone services), 25 times for 20 patients. In total William Tse billed 47 services in 8 codes, and Medicare paid $1,546.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99441 Telephone Services | Office | 25 | 20 | $23.29 | $582 |
By year: 2022 $7,816 for 117 services; 2023 $6,462 for 120 services; 2024 $1,546 for 47 services.
Medicare prescription drug claims, 2024
In 2024, the drug William Tse prescribed most often to Medicare patients was Imbruvica (Ibrutinib), with 57 prescriptions and refills. In total William Tse wrote 534 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | 57 | 67 | Under 11 | $811K |
| Jakafi Ruxolitinib Phosphate | 45 | 45 | Under 11 | $1.0M |
| Valacyclovir Valacyclovir Hcl | 40 | 48 | 11 | $1,676 |
| Dexamethasone Generic | 33 | 38 | Under 11 | $325 |
| Levothyroxine Sodium Generic | 31 | 52 | Under 11 | $175 |
| Lenalidomide Generic | 28 | 28 | Under 11 | $343K |
| Revlimid Lenalidomide | 25 | 25 | Under 11 | $587K |
| Hydroxyurea Generic | 25 | 50 | Under 11 | $419 |
| Brukinsa Zanubrutinib | 23 | 23 | Under 11 | $232K |
| Omeprazole Generic | 22 | 26 | Under 11 | $196 |
| Ondansetron Odt Ondansetron | 22 | 22 | Under 11 | $388 |
| Xpovio Selinexor | 21 | 21 | Under 11 | $642K |
| Pomalyst Pomalidomide | 20 | 20 | Under 11 | $467K |
| Prednisone Generic | 19 | 23 | Under 11 | $145 |
| Acyclovir Generic | 19 | 27 | Under 11 | $162 |
Brand drugs: 211 claims; generic drugs: 323 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Tse $6,904 ($6,904 in general payments such as food, travel and fees) from 11 companies. The largest payer was PharmaEssentia USA Corporation with $6,398.
| Company | Payments | Amount |
|---|---|---|
| PharmaEssentia USA Corporation 6446.TW | 5 | $6,398 |
| Incyte Corporation INCY | 4 | $155 |
| Genzyme Corporation SNY | 1 | $95.2 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $71.33 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $48.73 |
| Array Biopharma Inc PFE | 2 | $41.65 |
| Sobi, Inc SOBI.ST | 1 | $26.04 |
| Abbvie Inc. ABBV | 1 | $20.98 |
| Azurity Pharmaceuticals, Inc. | 1 | $17.43 |
| Pfizer Inc. PFE | 1 | $16.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.